208 related articles for article (PubMed ID: 30899608)
1. Abscopal Effect of Radiotherapy in Imatinib-resistant Dermatofibrosarcoma Protuberans.
Agyeman MB; Vanderpuye VD; Yarney J
Cureus; 2019 Jan; 11(1):e3857. PubMed ID: 30899608
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
3. Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P; Debiec-Rychter M
Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
[TBL] [Abstract][Full Text] [Related]
4. Abscopal effect triggered by radiation sequential mono-immunotherapy resulted in a complete remission of PMMR sigmoid colon cancer.
Zhou P; Wang Y; Qin S; Han Y; Yang Y; Zhao L; Zhou Q; Zhuo W
Front Immunol; 2023; 14():1139527. PubMed ID: 37020543
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
7. Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma.
Brenneman RJ; Sharifai N; Fischer-Valuck B; Hassanzadeh C; Guzelian J; Chrisinger JSA; Michalski JM; Oppelt P; Baumann BC
Front Oncol; 2019; 9():922. PubMed ID: 31616634
[No Abstract] [Full Text] [Related]
8. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
9. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
[TBL] [Abstract][Full Text] [Related]
10. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018.
Ugurel S; Kortmann RD; Mohr P; Mentzel T; Garbe C; Breuninger H; Bauer S; Grabbe S
J Dtsch Dermatol Ges; 2019 Jun; 17(6):663-668. PubMed ID: 31115967
[TBL] [Abstract][Full Text] [Related]
11. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
12. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.
Liu Y; Dong Y; Kong L; Shi F; Zhu H; Yu J
J Hematol Oncol; 2018 Aug; 11(1):104. PubMed ID: 30115069
[TBL] [Abstract][Full Text] [Related]
13. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.
Rodríguez-Ruiz ME; Vanpouille-Box C; Melero I; Formenti SC; Demaria S
Trends Immunol; 2018 Aug; 39(8):644-655. PubMed ID: 30001871
[TBL] [Abstract][Full Text] [Related]
14. Dermatofibrosarcoma protuberans - the use of neoadjuvant imatinib for treatment of an uncommon breast malignancy: a case report.
McGee MW; Boukhar SA; Monga V; Weigel R; Phadke SD
J Med Case Rep; 2019 Dec; 13(1):374. PubMed ID: 31852518
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
16. Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.
Tazzari M; Indio V; Vergani B; De Cecco L; Rini F; Negri T; Camisaschi C; Fiore M; Stacchiotti S; Dagrada GP; Casali PG; Gronchi A; Astolfi A; Pantaleo MA; Villa A; Lombardo C; Arienti F; Pilotti S; Rivoltini L; Castelli C
J Invest Dermatol; 2017 Feb; 137(2):484-493. PubMed ID: 27608549
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review.
Takahashi J; Nagasawa S
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297519
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade.
Zhao X; Shao C
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32992835
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.
Fu Y; Kang H; Zhao H; Hu J; Zhang H; Li X; Du N; Huang Y
Int J Clin Exp Med; 2015; 8(5):8288-94. PubMed ID: 26221412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
